Background
Phase 3, open-label, randomized controlled trial (EPIC). N=307 patients with newly diagnosed Ph+ CP-CML. Randomized 1:1 to ponatinib 45 mg vs imatinib 400 mg as frontline therapy. Ponatinib was being investigated in 1L based on superior response rates in pretreated patients (PACE). The trial was TERMINATED prematurely after a median ~5 months due to an unexpected excess of serious vascular adverse events (arterial thromboses) in the ponatinib arm identified during an unplanned safety review. Published Lancet Oncology 2016.
Interventions and follow up
Arm A: Ponatinib 45 mg PO once daily
Arm B: Imatinib 400 mg PO once daily
Primary endpoint: MMR at 12 months
Median follow-up: 5.1 months at trial termination (efficacy analysis at discontinuation)
Arm B: Imatinib 400 mg PO once daily
Primary endpoint: MMR at 12 months
Median follow-up: 5.1 months at trial termination (efficacy analysis at discontinuation)
Results
MMR (at termination): 40.5% (ponatinib) vs 24.2% (imatinib), numerically superior but trial terminated before full analysis
CCyR: 70.1% vs 52.6%
BCR-ABL IS <10% at 3 months: 94.1% (ponatinib) vs 81.6% (imatinib)
Serious arterial thrombotic events: 3.3% (ponatinib) vs 0.7% (imatinib) at median 5 months
Venous thromboembolism: 2.6% (ponatinib) vs 0%
CCyR: 70.1% vs 52.6%
BCR-ABL IS <10% at 3 months: 94.1% (ponatinib) vs 81.6% (imatinib)
Serious arterial thrombotic events: 3.3% (ponatinib) vs 0.7% (imatinib) at median 5 months
Venous thromboembolism: 2.6% (ponatinib) vs 0%
Adverse events
Vascular: 5 serious arterial events in the ponatinib arm (coronary artery occlusion, MI, peripheral arterial occlusion) vs 1 with imatinib within median 5-month exposure; hypertension grade ≥3 9.7% vs 1.3%
Other: Grade ≥3 AEs 54% (ponatinib) vs 40%; abdominal pain (pancreatitis signal) 9.1% vs 1.3%; rash 22.7% vs 3.3%; thrombocytopenia grade ≥3 13.0% vs 2.0%
Other: Grade ≥3 AEs 54% (ponatinib) vs 40%; abdominal pain (pancreatitis signal) 9.1% vs 1.3%; rash 22.7% vs 3.3%; thrombocytopenia grade ≥3 13.0% vs 2.0%
Conclusions
EPIC showed numerically superior early molecular responses for ponatinib vs imatinib in 1L CML but was terminated prematurely due to excess vascular events, establishing that ponatinib at 45 mg continuous dosing is unacceptably toxic for unselected newly diagnosed CML patients regardless of efficacy benefit. Ponatinib should not be used as frontline therapy in unselected CML.
Key Limitations
Trial terminated early, so formal statistical testing of the primary endpoint (MMR at 12 months) was not possible; efficacy conclusions are exploratory. The defining lesson was safety-driven: vascular toxicity at 45 mg continuous in low-risk, untreated patients substantially outweighs the incremental molecular response benefit. Short follow-up (median 5 months) precluded full quantification of cumulative ATE burden (projected 27% at 5 years per PACE). The OPTIC dose-reduction strategy (45→15 mg on BCR-ABL ≤1%) may rehabilitate ponatinib in selected high-risk 1L patients, but this is investigational and not standard.
Clinical Context
EPIC is an important negative trial that closed the door on ponatinib as standard frontline CML therapy. The FDA placed a partial clinical hold on new CML patients in 2013 during PACE safety review; ponatinib's label restricts use to T315I-mutant CML or CML resistant/intolerant to ≥2 TKIs. The 1L space is served by imatinib, nilotinib, dasatinib, and bosutinib without ponatinib's vascular risks. EPIC validated ATE risk as a class concern requiring careful patient selection. ESMO-MCBS: not assigned (terminated trial).